[EN] 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
申请人:CHONG KUN DANG PHARMACEUTICAL CORP
公开号:WO2020022794A1
公开(公告)日:2020-01-30
The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.
本发明涉及具有组蛋白去乙酰化酶6(HDAC6)抑制活性的新化合物,其光学异构体或其药学上可接受的盐,其药用用途以及其制备方法。根据本发明,这些新化合物,其光学异构体或其药学上可接受的盐具有组蛋白去乙酰化酶6(HDAC6)抑制活性,并且在预防或治疗与HDAC6相关的疾病方面具有有效性,包括传染病;肿瘤;内分泌;营养和代谢疾病;精神和行为障碍;神经系统疾病;眼部和眼附器疾病;循环系统疾病;呼吸系统疾病;消化系统疾病;皮肤和皮下组织疾病;肌肉骨骼系统和结缔组织疾病;以及畸形或变形和染色体异常。